*Shigella* is gram-negative bacterium that causes bacillary dysentery in human and non-human primates \[[@B1]-[@B4]\]. *Shigella flexneri* belonging to the B subgroup of the genus is a well-known pathogen for primates, chiefly responsible for morbidity and mortality in colonized monkeys \[[@B5]\]. Bloody diarrhea and mucus discharge is often accompanied with abdominal pain, tenesmus, fever, anorexia, weight loss and dehydration. In colonies of research macaques, *Shigella* infections are spread by the fecal-oral route, originating from the addition of animals that are asymptomatic carriers, either from the wild or from other colonies \[[@B1],[@B6]\]. In humans, persons traveling in areas with poor sanitation and crowded conditions become particularly susceptible to such diseases \[[@B7]-[@B9]\]. Importantly, *Shigella* is a zoonotic organism which could present in people working with nonhuman primates or *vice versa*.

Currently, a vaccine for *Shigella* has not been licensed in the United States and the organism quickly becomes resistant to medication. During the past 10 years, several live, attenuated oral *Shigella* vaccines, including the strains WRSs1, WRSs2 and WRSs3, are acceptable candidates for continued development as human *Shigella sonnei* vaccines \[[@B10]\]. However, commercial vaccine of *Shigella* is not yet used in the clinic for human and nonhuman primates. Thus, veterinary clinicians must assume shigellosis by clinical signs and instigate appropriate therapy or wait 24 to 48 h for the results of bacterial culture. For this reason, regular screening is necessary to prevent spreading of this pathogen to other individuals or colonies.

Recently, China has become one of the major breeders and suppliers of macaques for the biotech, pharmaceutical and medical communities worldwide. Also, our requirement of these animals is increasing in the field of biomedical research. Therefore, adequate prevention and prompt treatment of this pathogen is required to preserve a source of laboratory nonhuman primates in our country.

Here, we report that a newly acquired rhesus monkey infected by *Shigella flexneri* was precisely diagnosed and successfully treated with enrofloxacin. In addition, prompt treatment against this pathogen could control the spread of disease and preserve healthy colonies.

A 3.4-year-old male rhesus macaque, weighing 4.5 kg, was suffering from anorexia, acute mucous production and bloody diarrhea. The colony including this monkey was screened by the exporting country for bacterial and parasitic pathogens, such as *Mycobacterium*, *Salmonella*, *Shigella*, *Yersinia* and endo/ecto parasites. This rhesus macaque was imported from China and finished the legal quarantine process. Then, the colony including this monkey was acclimating at a laboratory animal facility which maintained at was 24±4℃ and a relative humidity of 50±10% with artificial lighting and a 12:12 light-dark cycle (7:00 AM onset) as well as with 13-18 air changes per h. This monkey was housed in an individual home cage and had daily provided food (PS DIET®, Oriental Yeast Co, Ltd, Japan and fresh fruits) and unlimited access to water. The animal was managed by the National Institutes of Health \"*Guide for the Care and Use of Laboratory Animals*\".

Fresh bloody diarrhea persisted for two days and gradually increased infrequency and volume, along with a foul smell ([Figure 1A](#F1){ref-type="fig"}). The perianal region was unclean with a bloody discharge ([Figure 1B](#F1){ref-type="fig"}). Vital signs recorded were as follows: body temperature (39.2), heart rate (250 beats/min) and respiratory rate (44 breaths/min). On physical examination, the monkey showed a loss of activity, hunched position, abdominal pain, dehydration and mild gingivitis. Differential diagnosis included parasitic, bacterial and viral infection. To rule out these factors, bloody stool was collected immediately for bacterial culture and then other laboratory tests were performed. Laboratory profiles revealed leukocytosis (14.5 K/µL) and neutrophilia (11.0 K/µL) on complete blood cell count as well as hyponatremia (139 mmol/L), hypokalemia (3.1 mmol/L) and hypochloremia (99 mmol/L) on electrolytes, and a normal range for serum chemistry. Based on the clinical signs, presumptive diagnosis was made as dysentery by *Shigella*, *Vibrio* or *Campylobacter* species. Preferentially, enrofloxacin (5 mg/kg, sid, intravenous or intramuscular injection) as an antibiotic for bacillary dysentery infection was administered for 3 days; bacterial cultures and parasitic examinations were also performed. No evidence of parasitic infection was found in the stool. On the other hand, the bacterial culture results showed growth of an unidentified organism.

To identify the organism, bloody stool samples were inoculated on MacConkey/Salmonella-Shigella agar (Mac/SSa) (Hanil Komed, Seoul, Korea) and incubated at 37℃. Colorless or black colonies grown on Mac/SSa were subcultured in blood agar ([Figure 2A](#F2){ref-type="fig"}). An IMVIC (Hanil Komed) test was negative for indole, motility and H~2~S in SIM broth, and negative in citrate, and K/A in triple sugar iron (TSI) agar ([Figure 2B](#F2){ref-type="fig"}). Also, colonies grown in thiosulfate-citrate-bile-sucrose (TCBS) media were negative for oxidase ([Figure 2C](#F2){ref-type="fig"}). *Vibrio spp*. and *Campylobacter spp*. were not detected in mCCDA and TCBS media. Finally, through the serological grouping using VITEK II, the organism was identified as *Shigella flexneri*. Consequently, the monkey was diagnosed as enterocolitis caused by *Shigella flexneri* and was continually treated with enrofloxacin. At post-onset day 5, bloody diarrhea completely disappeared and general body conditions recovered.

Asymptomatic carriers are common, especially in new world monkeys, and bacteriological screening is known to have low sensitivity \[[@B11]\]. Quarantine stations may perform routine stool-screening for enteric pathogens and commence antibiotic treatment, but this does not guarantee that animals remain free of infection on delivery to a primate facility. Organisms may continue to be shed intermittently, commonly at times of stress, such as when animals are in transit \[[@B11]\]. In these cases, the infected monkey has been examined regularly for enteric pathogens at the animal\'s breeding and pre-embarkation quarantine facility, and all animals are documented as negative in the individual records. However, a latent pathogen in this monkey was revealed at the time of post-transport and post-quarantine processes.

Clinical symptoms of shigellosis include mucus and bloody diarrhea, abdominal pain, nausea, vomiting and fever. Affected monkeys are weak and moderately to severely dehydrated, and they require prompt medical treatment to correct life-threatening fluid and electrolyte imbalances \[[@B12]\]. Fortunately, this monkey showed rapid recovery from the illness without electrolyte correction.The enteric pathogen *Shigella flexneri* has also been implicated as a cause of periodontal disease \[[@B13],[@B14]\]. This animal also showed mild gingivitis at both the upper/lower periodontal region, but has since been terminated. Diagnosis was based on clinical signs and isolation of the organism from deep rectal swabs and fresh stool specimens. Culture and isolation of the organism is facilitated by the use of selective media such as selenite broth and SSa agar \[[@B15]\].

Currently, no *Shigella* vaccine has been licensed, although several are under development \[[@B16]-[@B20]\]. China does not vaccinate for laboratory nonhuman primate colonies. For that reason, there is very high potential that asymptomatic carriers may spread pathogens to other monkeys or colonies. In this case, the infected monkey was newly imported from China and just finished the quarantine process when it showed clinical signs. It is suspected that asymptomatic monkeys reveal clinical signs by transport or environmental stress.

In this case, treatment of shigellosis was performed very rapidly and was completed by enrofloxacin administration. Enrofloxacin is a widely utilized antibiotic in veterinary medicine that has antibacterial activity against both gram-negative and gram-positive organisms \[[@B21],[@B22]\]. Enrofloxacin is generally regarded as not only an efficacious antibiotic, but also a safe drug \[[@B23]\].This treatment regimen was suggested successful in controlling *Shigella* in rhesus monkey based on clinical signs and successive cultures of rectal swabs from the infected monkey. In summary, our case suggests that a newly acquired rhesus monkey can be infected by *Shigella flexneri*, even with previous screening of bacterial and parasitic pathogens by the exporting country. It is considered that the infected monkey was an asymptomatic carrier and revealed clinical symptoms due to stressful environmental changes. Regular screening tests, control of transmission and aggressive treatment for this pathogen are essential for preservation of healthy nonhuman primate facilities.
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![(A) Fresh bloody stool lasting for two days, showed gradual increases in frequency and volume with a foul smell. (B) The perianal region was observed with a bloody discharge.](lar-27-343-g001){#F1}

![(A) Colorless or black colonies grown on the Mac/SSa were subcultured in BAP. (B) IMVIC test showed negative for indole, motility and H~2~S in SIM broth, negative in citrate and K/A in triple sugar iron agar. (C) Oxidase-negative result was seen for colony grown in thiosulfate-citrate-bile-sucrose media.](lar-27-343-g002){#F2}
